Medicina
Faculty
![Foto de Medicina](/img/uploaded/B3F8E74FDA254B3134B0031201D4E115.jpg)
![Foto de AstraZeneca (United Kingdom)](/img/noimage_org.png)
AstraZeneca (United Kingdom)
Cambridge, Reino UnidoPublications in collaboration with researchers from AstraZeneca (United Kingdom) (147)
2024
-
A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results
Annals of Oncology, Vol. 35, Núm. 8, pp. 707-717
-
Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase IIb multinational randomized double-blind placebo-controlled ARROYO trial
British Journal of Dermatology, Vol. 191, Núm. 2, pp. 187-199
-
Developing Therapies for C3 Glomerulopathy: Report of the Kidney Health Initiative C3 Glomerulopathy Trial Endpoints Work Group
Clinical Journal of the American Society of Nephrology
-
Durvalumab _ Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden
Clinical Cancer Research, Vol. 30, Núm. 4, pp. 824-835
-
Enhancing the management of chronic diseases in clinical practice: The CARABELA methodology
Journal of Healthcare Quality Research
-
Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
Frontiers in Neurology, Vol. 15
-
Lack of awareness of systemic lupus erythematosus and its consequences in a cohort of moderate and severe patients in Spain: The LupusVoice study
Lupus, Vol. 33, Núm. 7, pp. 663-674
-
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study
Molecular Cancer, Vol. 23, Núm. 1
-
Secondary Prevention Therapies in Real-World Patients with Myocardial Infarction: Eligibility Based on Randomized Trials Supporting European and American Guidelines
American Journal of Medicine, Vol. 137, Núm. 2, pp. 137-146.e10
-
TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy
Therapeutic Advances in Medical Oncology, Vol. 16
-
Trastuzumab deruxtecan in breast cancer
Critical Reviews in Oncology/Hematology, Vol. 198
2023
-
Burden of Illness beyond Mortality and Heart Failure Hospitalizations in Patients Newly Diagnosed with Heart Failure in Spain According to Ejection Fraction
Journal of Clinical Medicine, Vol. 12, Núm. 6
-
Cluster Analyses From the Real-World NOVELTY Study: Six Clusters Across the Asthma-COPD Spectrum
Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 9, pp. 2803-2811
-
Differences in clinical outcomes, health care resource utilization and costs in heart failure patients according to left ventricular ejection fraction
Revista Espanola de Cardiologia, Vol. 76, Núm. 11, pp. 862-871
-
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients with Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)
Journal of Clinical Oncology, Vol. 41, Núm. 1, pp. 43-53
-
Evolution of economic burden of heart failure by ejection fraction in newly diagnosed patients in Spain
BMC Health Services Research, Vol. 23, Núm. 1
-
Impact of standard modifiable cardiovascular risk factors on 2-year all-cause mortality: Insights from an international cohort of 23,489 patients with acute coronary syndrome
American Heart Journal, Vol. 264, pp. 20-30
-
Ravulizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder
Annals of Neurology, Vol. 93, Núm. 6, pp. 1053-1068
-
Real-World Evidence on the Clinical Characteristics and Management of Patients with Chronic Lymphocytic Leukemia in Spain Using Natural Language Processing: The SRealCLL Study
Cancers, Vol. 15, Núm. 16
-
Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy
Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 6, pp. 1759-1770.e7